ReviewThe Lancet. Oncology2024
Trends in nuclear medicine and the radiopharmaceutical sciences in oncology: workforce challenges and training in the age of theranostics.
Review in The Lancet. Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Assessing Value for Money in Theranostic Nuclear Medicine: A Systematic Review.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Pooled it
- In defence of the drug, two hearts, one profession: Reintegrating medicines expertise and patient-centred care in pharmacy's professional identity.Exploratory research in clinical and social pharmacy · 2026Article
- Physicians' knowledge, attitudes and practices on nuclear medicine in Cameroon: implications for medical education and health system planning in low- and middle-income countries.BMC health services research · 2026Article
- Soft skills for medical physicists: Evolving a profession.Journal of applied clinical medical physics · 2026Article
- Process-Related Incidents in Nuclear Medicine: A Four-Year Single-Center Retrospective Analysis to Support the Implementation of a Scenario-Based Radiopharmacy Training.Pharmacy (Basel, Switzerland) · 2026Article
- Combination therapy strategies in engineeredCell communication and signaling : CCS · 2026Review
- Future of radiotheranostics.BMJ oncology · 2026Review
- Clinical Applications of Theranostics.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026Review
- A century in the making: Medical imaging, nuclear medicine, and the transformation of global healthcare.European journal of nuclear medicine and molecular imaging · 2026Article
- Current and future perspectives on radioligand therapy in advanced prostate cancer.Therapeutic advances in medical oncology · 2026Review
- UAB/SNMMI Nuclear Medicine Therapy Intensive: Advancing Competence and Innovation in Radiopharmaceutical Therapy.Journal of nuclear medicine technology · 2025Article
- How Regulation 536/2014 Is Changing Academic Research with Therapeutic Radiopharmaceuticals: A Local Experience.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Review
- A preclinical and first-in-human study of superstable homogeneous radiolipiodol for revolutionizing interventional diagnosis and treatment of hepatocellular carcinoma.Acta pharmaceutica Sinica. B · 2025Article
- Theranostics in nuclear medicine: the era of precision oncology.Medical oncology (Northwood, London, England) · 2025Review
- Medicinal chemistry perspectives on anticancer drug design based on clinical applications (2015-2025).RSC advances · 2025Review
- Strategic Objectives of Nanotechnology-Driven Repurposing in Radiopharmacy-Implications for Radiopharmaceutical Repurposing (Beyond Oncology).Pharmaceutics · 2025Review
- Radiotheranostics in Low- and Middle-Income Countries: Challenges, Practice, and Prospects.World journal of nuclear medicine · 2025Review
- Multidisciplinary Perspectives of Clinical Trials in Theranostics.World journal of nuclear medicine · 2025Review
- Theranostics Implementation: Opportunities and Challenges.World journal of nuclear medicine · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
18 authors.
Funding
Abstract
Although the promise of radionuclides for the diagnosis and treatment of disease was recognised soon after the discovery of radioactivity in the late 19th century, the systematic use of radionuclides in medicine only gradually increased over the subsequent hundred years. The past two decades, however, has seen a remarkable surge in the clinical application of diagnostic and therapeutic radiopharmaceuticals, particularly in oncology. This development is an exciting time for the use of theranostics in oncology, but the rapid growth of this area of nuclear medicine has created challenges as well. In particular, the infrastructure for the manufacturing and distribution of radiopharmaceuticals remains in development, and regulatory bodies are still optimising guidelines for this new class of drug. One issue of paramount importance for achieving equitable access to theranostics is building a sufficiently trained workforce in high-income, middle-income, and low-income countries. Here, we discuss the key challenges and opportunities that face the field as it seeks to build its workforce for the 21st century.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.